Skip to main content

Table 1 Baseline characteristics and medication of all patients (n = 39) and healthy controls (HC, n = 19) included

From: IL-22 production of effector CD4+ T-cells is altered in SLE patients

  SLE patients HC p value
Total number 39 19  
Women/men 12/1 18/1 ns
Age (years, mean ± SD) 40 ± 14 36 ± 12 ns
SLEDAI (median, range) 2 (0–28)   
 Active disease (SLEDAI > 4) (n) 7   
 Inactive disease (SLEDAI ≤ 4) (n) 32   
Treatment, n    
 None 1 19  
 Glucocorticoids, n 32   
  Median dose (range), dose (mg/day) 5 (2.5–60)   
Immunosuppressive/immune-modulating    
 Hydroxychloroquine, n 17   
  Median dose (range), users (mg/day) 200 (200–400)   
 Methotrexate, n 2   
  Median dose (range), users (mg/week) 15 (15–15)   
 Azathioprine, n 9   
  Median dose (range), users (mg/day) 125 (25–250)   
 MMF, n 14   
  Median dose (range), users (mg/day) 1500 (360–2000)   
 Cyclophosphamide, n 3   
  Median dose (range), users (mg/day) 200 (100–300)   
  1. SLEDAI systemic lupus erythematosus Disease Activity Index, MMF mycophenolate mofetil